Status of Antiarrhythmic Drug Development for Atrial Fibrillation: New Drugs and New Molecular Mechanisms

Circ Arrhythm Electrophysiol. 2016 Mar;9(3):e002479. doi: 10.1161/CIRCEP.115.002479.

Authors

Colleen M Hanley¹, Victoria M Robinson², Peter R Kowey²

Affiliations

¹ From the Cardiology Division (C.M.H., P.R.K.) and Lankenau Institute for Medical Research (V.M.R., P.R.K.), Lankenau Medical Center, Wynnewood, PA. HanleyC@MLHS.org.
² From the Cardiology Division (C.M.H., P.R.K.) and Lankenau Institute for Medical Research (V.M.R., P.R.K.), Lankenau Medical Center, Wynnewood, PA.

PMID: 26936819
DOI: 10.1161/CIRCEP.115.002479

No abstract available

Keywords: amiodarone; atrial fibrillation; catheter ablation; flecainide; vernakalant.

Publication types

Review

MeSH terms

Action Potentials
Animals
Anti-Arrhythmia Agents / adverse effects
Anti-Arrhythmia Agents / therapeutic use*
Atrial Fibrillation / diagnosis
Atrial Fibrillation / drug therapy*
Atrial Fibrillation / metabolism
Atrial Fibrillation / physiopathology
Drugs, Investigational / adverse effects
Drugs, Investigational / therapeutic use*
Heart Conduction System / drug effects*
Heart Conduction System / metabolism
Heart Conduction System / physiopathology
Heart Rate / drug effects*
Humans
Molecular Targeted Therapy
Treatment Outcome

Substances

Anti-Arrhythmia Agents
Drugs, Investigational